



**Contact:**

David Waldman or Justyna Gudaszewska  
Crescendo Communications Europe Sp. z o.o.  
Email: [mmd@crescendo-ir.com](mailto:mmd@crescendo-ir.com)  
Tel: + 48 71 79 11 551

**Milestone Medical Inc. Announces Successful Interim Analysis of Clinical Trials  
for its Epidural Instrument**

*Interim Analysis Achieves Goal Set by the FDA IDE Investigational Plan*

**LIVINGSTON, NJ, August 19, 2015 -- Milestone Medical Inc. (WAR: MMD)**, today announced successful results of the interim analysis of the COMPASS Study (CompuFlo® Assessment Study), a randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System.

Milestone Medical further announced the clinical trial for the epidural instrument has reached an enrollment of 200 patients. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo technology in identifying and confirming the epidural space location.

Leonard Osser, Chief Executive Officer of Milestone Medical, stated, "The interim analysis of the COMPASS Study clearly achieved the goal set by the FDA IDE Investigational Plan. We look forward to expeditiously continuing our enrollment and completing our trial later this year."

"With the U.S. epidural market estimated at over \$7 billion annually and over 2.4 million women receiving epidurals, we believe this instrument will help reduce health risks to patients and malpractice risk to medical professionals administering epidurals," concluded Mr. Osser.

**About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery instruments based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval in the U.S. and has recently received CE approval for both instruments in the European Union. For more information please visit [www.medicalmilestone.com](http://www.medicalmilestone.com).

**Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this*

*press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*

**# # #**